Status:
COMPLETED
VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the impact of supportive measures on the drug adherence of patients with essential hypertension
Eligibility Criteria
Inclusion
- Male or female patients \>= 18 years
- Females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine device, hormonal contraceptives).
- Patients with mild essential hypertension: Systolic blood pressure ≥ 140 mmHg and \< 170 and/or diastolic blood pressure ≥ 90 mmHg and \< 105 mmHg"
Exclusion
- Moderate and severe hypertension
- Pregnant or nursing women
- A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure NYHA II - IV
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT00394823
Start Date
November 1 2005
End Date
June 1 2007
Last Update
May 18 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Centers, Germany
2
Novartis
Basel, Switzerland